SORRENTO THERAPEUTICS, INC. Form 8-K (March 5, 2020)

Summary

Current report on Form 8-K for an event dated March 5, 2020, filed by Sorrento Therapeutics, Inc. Under Item 8.01, the report states that on March 5, 2020, the company filed a legal action against Patrick Soon-Shiong in Los Angeles Superior Court, asserting claims for fraudulent inducement and common law fraud arising out of Dr. Soon-Shiong's purchase of the drug Cynviloq from the company in May 2015. The action alleges, among other things, that Dr. Soon-Shiong acquired Cynviloq for the purpose of halting its progression to the market. The company dismissed Dr. Soon-Shiong from the related, ongoing arbitration against NantPharma, LLC. Henry Ji signed on March 6, 2020.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Cite this document

“SORRENTO THERAPEUTICS, INC. Form 8-K (March 5, 2020).” Original at www.sec.gov. Archived at Pandemic Darlings, https://pandemicdarlings.com/source-documents/sec-srne-8-k-filed2020-03-06-0001104659-20-030232-7f0d074021/, SHA-256 f3226910efa9b23ef3fce650dbba920f00c7de4a8bae448b73b7ac2b2e531a23.

Full text

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event
reported): March 5, 2020

SORRENTO THERAPEUTICS, INC.

(Exact Name of Registrant as Specified
in its Charter)

Delaware | 001-36150 | 33-0344842
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.)

4955 Directors Place

San Diego , CA 92121

(Address of Principal Executive Offices)
(Zip Code)

Registrant’s telephone number,
including area code: ( 858 ) 203-4100

N/A

(Former Name, or Former Address, if Changed
Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities Registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol | Name of each exchange on which registered
Common Stock, $0.0001 par value | SRNE | The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01 Other Information .

On March 5, 2020, Sorrento Therapeutics,
Inc. (the “Company”) filed a legal action against Patrick Soon-Shiong in Los Angeles Superior Court, asserting claims
for fraudulent inducement and common law fraud, arising out of Dr. Soon-Shiong’s purchase of the drug Cynviloq TM from the Company in May 2015. The action alleges that, among other things, Dr. Soon-Shiong acquired the drug Cynviloq for the purpose
of halting its progression to the market. In connection with filing this civil action in the Los Angeles Superior Court, where
the Company will have the right to a jury trial against Dr. Soon-Shiong, the Company has dismissed Dr. Soon-Shiong from the related,
ongoing arbitration against NantPharma, LLC.

SIGNATURES

Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SORRENTO THERAPEUTICS, INC.
Date: March 6, 2020 | By: | /s/ Henry Ji, Ph.D.
Name: Henry Ji, Ph.D.
Title: Chairman, President and Chief Executive Officer

File and source

File: SEC_SRNE_8-K_filed2020-03-06_0001104659-20-030232.htm
Size: 24,119 bytes
SHA-256: f3226910efa9b23ef3fce650dbba920f00c7de4a8bae448b73b7ac2b2e531a23
Our copy: SEC_SRNE_8-K_filed2020-03-06_0001104659-20-030232.htm
Original: www.sec.gov